Cellectar Biosciences, Inc. · NASDAQ:CLRB
Cellectar Biosciences — Investor Presentation (December 2016)
30 slides from Cellectar Biosciences's investor presentation, December 2016
Slide 1: Cellectar Biosciences
'G; @se CELLECTAR BIOSCIENCES NASDAQ: CLRB
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that ma
Slide 3: Company Overview
Company Overview • Oncology-focused biopharmaceutical company in Madison, WI • Rapid company transformation – Strategy and therapeutic product focus – Financial Efficiency - Improved R&D and SG&A expenses • Phospholipid Drug Conjugate (PDC) Delivery Platform – Phospholipid Ether cancer-targeting veh
Slide 4: Phospholipid Ether Cancer-Targeting Vehicle
Phospholipid Ether Cancer-Targeting Vehicle • Proprietary small-molecule • Highly selective cancer and cancer stem cell (CSC) targeting • Uptake and prolonged retention in malignant cells – Proof of concept (POC) in broad range of cancers • Ability to attach diverse oncologic payloads • Extensive re
Slide 5: PDC Delivery Platform Overview
PDC Delivery Platform Overview Phospholipid Drug Conjugate (PDC) Fluorophores Phospholipid Ether + Linker + Drug = PDC (PLE) Linker Radioisotopes Chemotherapeutics Validated Targeted Delivery of Diverse Oncologic Payloads 5 Data source: In house data, on file.
Slide 6: PDC Cancer-Targeting Validation in Broad Range of Cancers
PDC Cancer-Targeting Validation in Broad Range of Cancers In Vitro Mechanistic POC Malignant vs normal Prostate Glioma stem cells Multiple Myeloma • Lipid Raft Uptake • Cytoplasm & Cell Organelle Delivery • Prolonged Retention In Vivo POC • 70+ Cancer & CSC Models • Therapeutics & Imaging Colon Panc
Slide 7: PDC vs. ADC Targeting & Payload Delivery
PDC vs. ADC Targeting & Payload Delivery Phospholipid Ether-Drug Conjugates Antibody-Drug Conjugates Target: Lipid rafts/ Caveolae Target: Tumor-specific antigens Delivery: Cell cytoplasm Delivery: Cell surface Immunogenic: No Immunogenic: Potentially PDCs Exploit An Unalterable Metabolic Pathway 7
Slide 8: PDC Delivery Platform Summary
PDC Delivery Platform Summary DELIVERY PLATFORM PDC ADC Description PLE: Small-Molecule Antibody: Biologic Cancer Targeting Cancer Stem Cell Targeting Metastases Targeting Ability to Overcome Resistance Safety Cytoplasm Payload Delivery Payload Diversity Linker Options Manufacturing Cost/Complexity
Slide 9: PDC Product Development Pipeline
PDC Product Development Pipeline PDC Program Payload Indication Discovery Pre-IND Phase I Phase II Collaboration Multiple Myeloma Phase I CLR 1311 Iodine-131 Hematologic Malignancies Phase II- Expected Q1 2017 CTX CLR 1800-P Proprietary TBD2 Pre-IND CTX Performance- CLR 1602-PTX3 Paclitaxel based Pr
Slide 10: CLR 131: PDC Radiotherapeutic Overview
CLR 131: PDC Radiotherapeutic Overview • Targeted, precision radiotherapeutic – Novel mechanism of action • Phase I maximum tolerated dose study in R/R multiple myeloma – Demonstrates early signs of efficacy & tolerability • Improved performance from Cohort 1 to Cohort 2 – Progression-free survival
Slide 11: Multiple Myeloma Target Product Profile
CLR 131: Multiple Myeloma (MM) Target Product Profile Decision Category Top Decision Attributes CLR 131 MM Profile Treatment of relapse/refractory patients having Indication (Area of unmet need) Treatment of relapse/refractory patients having received a minimum of 2 lines of prior therapy received a
Slide 12: CLR 131: Clinical Development Strategy
CLR 131: Clinical Development Strategy • Near-term Hematologic Malignancy Focus – Indications with established radiosensitivity – Orphan designations – High rate of relapse/resistant disease settings – Niche opportunities with high unmet medical need • Multiple Myeloma – Incurable – Surrogate marker
Slide 13: Non-dilutive NCI Funding
CLR 131: Non-dilutive NCI Funding August 3, 2016 13
Slide 14: Phase I R/R Multiple Myeloma Study Overview
CLR 131: Phase I R/R Multiple Myeloma Study Overview • Multi-center, Open Label, Dose Escalation Trial Initiated Q2 2015 • Primary Objective: – Characterize safety & tolerability • Secondary Objectives: – Establish Phase II dose – Assess therapeutic activity • Dose Escalation < 2 of 6 DLT’s • 85 Day
Slide 15: Cohort 1 & Cohort 2 Patient Demographics
CLR 131: Cohort 1 & Cohort 2 Patient Demographics Cohort #1 Cohort #2 Demographic Metric (12.5 mCi/m2) (18.75 mCi/m2) Evaluable Patients 4 4 Average Age 68 69 Gender (Female:Male) 1:3 2:2 Prior Treatment Lines 41/6.52 4 Prior Proteasome Inhibitor and IMiD Trx 4/4 4/4 Prior Rev, Velcade, Dex Trx, 4/4
Slide 16: Cohort 1 & 2 Efficacy Markers: M-Protein
CLR 131: Cohort 1 (12.5 mCi/m2) & 2 (18.75 mCi/m2) Efficacy Markers AVERAGE M-PROTEIN M-PROTEIN 1 15 0 10 -1 AVERAGE REDUCTION FROM BASELINE (%) 5 REDUCTION FROM BASELINE (%) -2 0 131 Dose -3 -5 -4 -10 -5 -15 -6 -20 -7 -8 -25 -9 -30 -10 -35 Screening 22 43 64 Screening 22 43 64 85 DAYS POST SINGLE D
Slide 17: Cohort 1 & 2 Efficacy Markers: Free Light Chain
CLR 131: Cohort 1 (12.5 mCi/m2) & 2 (18.75 mCi/m2) Efficacy Markers 0.0% I-131 D1 FREE LIGHT CHAIN (FLC) -10.0% -20.0% REDUCTION FROM BASELINE (%) -30.0% Cohort 1 N=2 -40.0% Cohort 2 N=2 -50.0% Partial Repsonse1 -60.0% -70.0% -80.0% 1 22 43 64 85 DAYS POST SINGLE DOSE 1. IMWG Criteria, If Serum or U
Slide 18: Cohort 1 & 2 Efficacy Markers: PFS and mOS
CLR 131: Cohort 1 (12.5 mCi/m2) & 2 (18.75 mCi/m2) Efficacy Markers Progression Free Survival (PFS) Performance1 Median Overall Survival (mOS) Performance1 CLR 131 – PHASE I CLR 131 – PHASE I 140 12 +43% 11.9 11 Months MEDIAN OVERALL SURVIVAL (MONTHS) PROGRESSION FREE SURVIVAL (DAYS) 127 120 128 Day
Slide 19: Efficacy Markers For Recently Approved Drugs
Efficacy Markers For Recently Approved Drugs Progression Free Survival (PFS) Performance Median Overall Survival (mOS) Performance 140 20 11.9 MEDIAN OVERALL SURVIVAL (MONTHS) PROGRESSION FREE SURVIVAL (DAYS) 18 Months 18.6 120 Months 128 Days 127 Days120-138 Days 16 111 111 Days Days 100 14 O 89 12
Slide 20: CLR 131: Adverse Event Profile
CLR 131: Adverse Event Profile • Positive Safety Profile Through 2 Cohorts and 281 Patient Data Set – No neuropathies – No nephrotoxicity – No cardiotoxicities – No GI2 toxicities – No DVT3 – Most common AEs hematological in nature Adverse Events Avg. Number/Patient Avg. Grade/Patient Median Grade C
Slide 21: Multiple Myeloma Market Overview
CLR 131: Multiple Myeloma Market Overview • Unmet Need Remains in The Relapsed or Refractory (R/R) Setting • Annual U.S.: 2nd Most Common Hematologic Cancer1 – Prevalence ~ 90,000 – Incidence ~ 30,330 – Relapsed/Refractory ~ 13,000 • MM Drug Market – $8.9B (2014) - $22.4B (2023) – CAGR 11.2%2 – Aver
Slide 22: Phase II Study in Relapse Refractory B-cell Malignancies
CLR 131: Phase II Study in Relapse Refractory B-cell Malignancies 20-30 Multiple Repeat all efficacy assessments Myeloma Optional 20-30 Second Dose CLL1/SLL2, (Day 75 – 180) MZL3, LPL4 Efficacy Assessments ~120 Patients Primary End Point: Screened Overall Response Rate 20-30 Mantle Follow-up Cell ly
Slide 23: HemOnc Market Opportunity
CLR 131: HemOnc Market Opportunity Relapsed/Refractory $850+ Million Annual Top Line Revenue Potential1 • Multiple Myeloma $1,000,000,000.00 $900,000,000.00 • Diffuse Large B Cell Lymphoma $800,000,000.00 • Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma $700,000,000.00 • Marginal Zone Lymp
Slide 24: PDC Chemotherapeutic Program Overview
PDC Chemotherapeutic Program Overview • Objective – Develop chemotherapeutic PDCs with improved efficacy & tolerability • Clinical Rationale – Chemotherapeutics highly effective, yet highly toxic drugs – Combining the unique targeting capabilities of PDCs with cytotoxic drugs improves therapeutic in
Slide 25: Pierre Fabre PDC Collaboration
Pierre Fabre PDC Collaboration • Announced December 2015 – Launched Q1 2016 • Pierre Fabre provides selection of proprietary cytotoxins • Objectives – Co-design library of PDCs • Lead product conjugation completed – Conduct in vitro assessments – Conduct in vivo POC studies • Targeting/biodistributi
Slide 26: Financial Summary
Financial Summary Capitalization as of December 16, 2016 Common Stock Outstanding 9,634,988 Reserved for Issuance: Warrants 10,716,952 1 Convertible Preferred Stock 1,866,676 Employee Options 472,775 Fully Diluted 22,691,391 2 Pro Forma Cash (Q3 balance plus Nov. financing) $ 13,900,000 Cost Efficie
Slide 27: 2016 Company Developments
2016 Company Developments Q1 - Q2 2016 Q3 2016 Q4 2016 ✓ Pierre Fabre - Q1 -PDC Collaboration Initiated ✓ CLR 131 $2M NCI Fast Track Award - Q3 -Contract Granted -Phase II Clinical Study in Hematologic Cancers ✓ CLR 131 $2M NCI Fast Track Award - Q4 -Phase II Study Design Announced ✓ $8M Financing C
Slide 28: 2017 Company Developments: Clinical Events
2017 Company Developments: Clinical Events CLR 131 Phase I Clinical Study, Cohort 3: • (25 mCi) Fully Enrolled • Data release(s) CLR 131 Phase I Clinical Study, Cohort 4: • Initiation As Required Per Study Protocol Q1 2017 Q2 2017 Q3 2017 Q4 2017 CLR 131 Phase II Clinical Study: CLR 131 Phase II Dat
Slide 29: Company Leadership
Company Leadership Management Independent Directors HIP Faraday Pharmaceuticals- CEO; Jim HIP Innovation Innovation Technology- Technology- EVP EVP & & Stephen A. Hill, B.M. Jim Caruso Caruso COO; Allos Therapeutics- EVP & CCO; Targacept- President and CEO; Solvay President, COO; Allos Therapeutics-
Slide 30: Company Overview
Company Overview • Oncology-focused biopharmaceutical company in Madison, WI • Rapid company transformation – Company strategy and product focus – Financial Efficiency - Improved R&D and SG&A expenses • Phospholipid Drug Conjugate (PDC) Delivery Platform – Phospholipid Ether cancer-targeting vehicle
Cellectar Biosciences — Investor Presentation (December 2016) on 6ix